A Warm Welcome To Martin MacLean

We at Global Law Experts welcome Martin MacLean as our Exclusive Member for Patent in the United Kingdom. Martin is a recognised leader in Patent law in the United Kingdom, bringing a rare combination of scientific depth and courtroom proven advocacy that speaks directly to the needs of life sciences innovators, investors & in house counsel.

About Martin MacLean’s Expertise

Martin MacLean is a partner in the life sciences team at Mathys & Squire LLP. He is qualified as both a UK and European patent attorney and has more than two decades of experience in high value biotechnology and pharmaceutical matters.

His academic foundation includes a first class undergraduate degree and a PhD in microbial engineering from the University of Warwick, complemented by postgraduate study in intellectual property, which supports his work on technically sophisticated patent portfolios.

Martin’s practice covers patent drafting, global prosecution, opposition & appeal work at the European Patent Office, along with strategic freedom to operate analysis and transaction focused due diligence for assignments and acquisitions.

He regularly handles matters involving protein therapeutics, antibodies, vaccines, expression systems and diagnostic assays, where the technical record and claim language determine commercial value.

Verified Track Record & Professional Recognition

Martin has an established record of EPO advocacy, including well in excess of 100 EPO hearings and a high success rate at opposition and appeal stages. This practical appellate experience makes him a frequent choice in matters involving validity challenges, complex oppositions or litigation support.

His market recognition is reflected in consistent directory rankings and peer commentary, including Band 1 listings in the Chambers & Partners guide and regular inclusion in IAM Strategy 300 and IAM Patent 1000, signaling sustained excellence in life sciences patent work. These endorsements explain why sophisticated organisations seek his guidance for portfolio design and contested EPO work.

Select Publications & Thought Leadership

Martin contributes to practitioner scholarship on cutting edge biological therapeutics. Notably, he co authored a chapter on intellectual property issues for bacteriophages in a Springer volume, reflecting engagement with novel therapeutic modalities and the patentability questions they raise. This specialist commentary helps clients navigate IP issues for emergent technologies where precedent is still developing.

He also participates regularly in webinars and practitioner events on topics such as antibody inventive step at the EPO and patent drafting strategies tailored to European prosecution practice, demonstrating a practical, education focused approach to complex subject matter.

Why Global Law Experts Is Proud To Feature Martin MacLean

At Global Law Experts we prioritise members who combine technical mastery with demonstrable, repeatable client outcomes. Martin’s blend of PhD level science, appellate experience and portfolio level commercial judgment meets this standard: he designs protection that aligns with business risk, regulatory timelines and transaction drivers rather than pursuing maximalist claim sets that invite unnecessary challenges.

Mathys & Squire’s life sciences capability, in which Martin is a senior figure, is recognised in leading legal directories, reinforcing the firm context in which he delivers advice and advocacy. Featuring Martin as an Exclusive Member strengthens our ability to connect clients in the United Kingdom with a patent lawyer who understands both laboratory science and the business of IP.

Patent Law In United Kingdom: The Current Landscape

Patent law in the United Kingdom remains a cornerstone for protecting life sciences innovation, but practitioners must navigate a layered system that includes domestic law, UK court decisions, and EP validated European patents. The Patents Act 1977 and related case law provide the framework, while European patents granted by the EPO continue to offer regional coverage. Expert guidance is essential to translate research outcomes into enforceable, commercially valuable rights.

Post Brexit adjustments and evolving national practice require careful attention to interactions between EPO procedures, UK national validation, and regulatory exclusivities such as SPCs. SPCs play a critical role for many pharmaceutical and agrochemical products and have seen statutory and procedural changes in recent years. In particular, rules about which marketing authorisations can support a UK SPC and the steps needed to preserve protection across Great Britain and Northern Ireland have been the subject of government guidance. Careful planning around SPC timelines remains a vital part of portfolio strategy.

Key Challenges For Life Sciences Innovators

Businesses operating in therapeutics, diagnostics and agricultural tech face recurring challenges under patent law in the United Kingdom: drafting precise claims that withstand EPO scrutiny; protecting multi component biologics with balanced method, composition and use claims; anticipating oppositions; and aligning patent term strategies with regulatory exclusivities such as SPCs. These technical and procedural demands make specialist counsel indispensable at the earliest stages of R&D.

Freedom to operate analysis is another practical hurdle: a robust patent landscape opinion requires both technical acumen and an appreciation of commercial risk. Whether preparing for licensing, fundraising, clinical trials or an exit, clients need opinions that reconcile scientific uncertainty with enforceability and infringement exposure across multiple jurisdictions. Practitioners with both prosecution and opposition expertise like Martin are well placed to translate those risks into actionable strategies.

How Martin MacLean Advises Clients On High‑Value Portfolios

Martin’s approach is pragmatic and prioritized: he focuses protection where it delivers business value, engages early on claim drafting to secure globally viable scopes, and uses his EPO appeal experience to defend priority rights when challenged. In transactions, his technical due diligence supports deals of substantial value by identifying patent strengths, prosecution shortcomings and potential litigation exposure.

Clients from start ups to multinational corporations seek him when they need a partner who can translate bench science into enforceable IP assets, lead oppositions or appeals at the EPO, and structure portfolios to support licensing, collaboration and commercialization. This combination of drafting, prosecution and appellate skill is particularly valuable where biological nuance such as antibodies or bacteriophage technologies drives claim scope.

Who Should Seek Martin MacLean’s Advice

Businesses and individuals seeking counsel on patent law in the United Kingdom should consider Martin where life sciences technology forms the core asset especially in protein therapeutics, vaccines, diagnostics, biologically derived agrochemicals and related platform technologies. He is well suited to clients facing oppositions or appeal proceedings at the EPO, those preparing for M&A or licensing transactions with significant IP risk, and innovators needing global prosecution strategies that balance breadth with enforceability.

Early stage enterprises benefit from Martin’s emphasis on drafting that preserves global options, while mature organisations rely on his experience to streamline portfolios, resolve contested proceedings, and advise on regulatory planning such as SPC timing and maintenance. His combined scientific training and extensive EPO experience make him an effective advisor at every stage of an IP lifecycle.

Final Thoughts

Patent law in the United Kingdom rewards advisers who bridge rigorous science with procedural mastery, and Martin MacLean embodies that hybrid capability. At Global Law Experts we are pleased to welcome him as our Exclusive Member for Patent to offer clients access to a practitioner trusted for high stakes patent prosecution, opposition and commercial IP strategy.

If your business depends on life sciences IP, partnering with a specialist who understands laboratory complexity and the demands of European and UK patent practice can materially affect outcomes whether securing a grant, defending validity, or preparing for commercialisation. Martin’s record of advocacy, scholarship and client service positions him to advise on these matters with clarity and commercial rigour.